Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4403968 | 1.00 | KIF11 (0.38) | KIF11DNMT1 | |
| SCHEMBL14537504 | 0.90 | KIF11 (0.48) | KIF11DNMT1 | |
| SCHEMBL14432713 | 0.89 | KIF11 (0.49) | KIF11 | |
| SCHEMBL14432712 | 0.89 | KIF11 (0.49) | KIF11 | |
| SCHEMBL2672081 | 0.74 | MAPT (0.38) | — | |
| SCHEMBL2672073 | 0.74 | MAPT (0.38) | — | |
| SCHEMBL16903961 | 0.74 | L3MBTL1 (0.50) | — | |
| SCHEMBL12482199 | 0.74 | L3MBTL1 (0.50) | — | |
| SCHEMBL12334225 | 0.74 | — | — | |
| SCHEMBL11957550 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252596-B1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | UNIV MARQUETTE (US) | 2016-12-28 | — | — | EP | disclosed |
| US-20150175559-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY (US) | 2015-06-25 | — | — | US | disclosed |
| US-8962692-B2 | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings | MARQUETTE UNIVERSITY (US) | 2015-02-24 | — | — | US | disclosed |
| US-8765817-B1 | Selective inhibitors of EG5 motors and methods of use | ARROWHEAD CENTER, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8435997-B2 | Cysteine prodrugs to treat schizophrenia and drug addiction | MARQUETTE UNIVERSITY (US) | 2013-05-07 | — | — | US | disclosed |
| US-8349899-B1 | Selective inhibitors of EG5 motors and methods of use | ARROWHEAD CENTER, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120220596-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | UWM RESEARCH FOUNDATION, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8173809-B2 | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings | MARQUETTE UNIVERSITY (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110021533-A1 | CYSTEINE PRODRUGS TO TREAT SCHIZOPHRENIA AND DRUG ADDICTION | MARQUETTE UNIVERSITY (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2252596-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | Marquette University (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7829709-B1 | Cysteine prodrugs to treat schizophrenia and drug addiction | MARQUETTE UNIVERSITY (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090281109-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY | 2009-11-12 | — | — | US | disclosed |
| WO-2009100431-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100431-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281109-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | CTH, SLC7A11, CBS | KIF11 4584/4885DNMT1 1840/4885 |
| US-20120220596-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | CTH, SLC7A11, CBS | KIF11 4584/4885DNMT1 1840/4885 |
| US-20150175559-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | SLC7A11, CBS, CTH | KIF11 4330/4885DNMT1 1348/4885 |
| US-20110021533-A1 | CYSTEINE PRODRUGS TO TREAT SCHIZOPHRENIA AND DRUG ADDICTION | CTH, CBS, SLC6A3 | KIF11 4498/4885DNMT1 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.